Evolving Concepts of Type 2 Diabetes Management

Med Clin North Am. 2021 Nov;105(6):955-966. doi: 10.1016/j.mcna.2021.06.003. Epub 2021 Sep 9.

Abstract

With the concept of patient-centered care in mind, this article outlines the current diabetes medications available for glucose lowering and the characteristics of each of these medications that need to be considered in shared decision-making for durable and effective therapy. Important patient characteristics such as weight, risk for hypoglycemia, cost, social determinants of health, and medical literacy need to be considered. The evidence-base informing the use of antihyperglycemic agents has changed dramatically due to 2008 FDA guidance for cardiovascular safety and cardiorenal protection with antihyperglycemic agents. New evidence supports an approach to diabetes management that addresses pre-existing cardiorenal disease.

Keywords: Atherosclerotic cardiovascular disease; Cost; Heart failure; Microvascular complications; Obesity; Patient-centered care; Type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / prevention & control
  • Clinical Trials as Topic
  • Comorbidity
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
  • Drug Therapy, Combination
  • Glucagon-Like Peptide-1 Receptor / agonists
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / therapeutic use
  • Life Style
  • Practice Guidelines as Topic
  • Prospective Studies
  • Renal Insufficiency, Chronic / prevention & control
  • Risk Factors
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
  • Sulfonylurea Compounds / therapeutic use
  • Thiazolidinediones / therapeutic use

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Insulin
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sulfonylurea Compounds
  • Thiazolidinediones
  • 2,4-thiazolidinedione